SCHEMBL14201480

SCHEMBL14201480

NC(CF)(C(=O)O)C(O)CCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
HIF1A Q16665 1/20 0.42
ANPEP P15144 2/20 0.41
ERAP1 Q9NZ08 2/20 0.41
ERAP2 Q6P179 1/20 0.41
METAP2 P50579 1/20 0.40
METAP1 P53582 1/20 0.40
CNR2 P34972 1/20 0.40
TSHR P16473 1/20 0.40
TRPA1 O75762 1/20 0.39
DPP4 P27487 1/20 0.39
HPGD P15428 2/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
GRM2 Q14416 1/20 0.38
GRM3 Q14832 1/20 0.38
KEAP1 Q14145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14201435 0.90 TRPA1 (0.49) SMN1; SMN2TRPA1GRM2GRM3
SCHEMBL14145254 0.78 GRIK1 (0.47) SMN1; SMN2HIF1ATRPA1MMP2GRM2
SCHEMBL4737745 0.78 GRIK1 (0.47) SMN1; SMN2HIF1ATRPA1MMP2GRM2
SCHEMBL14201456 0.78 TSHR (0.45) SMN1; SMN2HIF1AANPEPERAP1ERAP2
SCHEMBL14145649 0.77 ALDH1A1 (0.42) SMN1; SMN2ANPEPERAP1ERAP2METAP2
SCHEMBL7268813 0.77 CES1 (0.44) SMN1; SMN2ANPEPERAP1ERAP2CNR2
SCHEMBL16419905 0.73 TSHR (0.47) SMN1; SMN2CNR2TSHRTRPA1DPP4
SCHEMBL6720239 0.73 LMNA (0.40) SMN1; SMN2HIF1AGRM2GRM3
SCHEMBL8067994 0.73 SLC6A2 (0.45) SMN1; SMN2ANPEPERAP1ERAP2TSHR
SCHEMBL837930 0.72 MMP13 (0.47) ANPEPERAP1ERAP2HPGDMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096799-A1 COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION FORBES MEDI-TECH (RESEARCH), INC. (US) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096799-A1 COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION PNLIP, CPT1A, CPT1B SMN1; SMN2 1317/4885HIF1A 650/4885ANPEP 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.